Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study

• Published in: Vaccine 2024-01, Vol.42 (3), p.522-528
• Main Authors: Shenton, Priya, Schrader, Silja, Smith, Julia, Alafaci, Annette, Cox, Nicholas, Taylor, Andrew, Hare, James, Jones, Bryn, Crawford, Nigel W., Buttery, Jim P, Cheng, Daryl R.
• Format: Article
• Language: English
• Subjects: Adverse events; Age; Bacterial infections; Cardiomyopathy; Clinical outcomes; COVID-19; Covid-19 Vaccinations; COVID-19 vaccines; Females; Health surveillance; Heart diseases; Infections; Laboratories; Males; Morbidity; mRNA vaccines; Myocarditis; Myopericarditis; Population; Surveillance; Surveys; Troponin; Vaccine safety surveillance; Vaccines; Viral infections; Young adults
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2023.12.070

•Myocarditis is a well known adverse events of special interest following COVID-19 vaccines.•Limited information has been published regarding medium and longer term outcomes.•This clinical survey study found around half of patients still experience symptoms at 6 months.•There are distinct phenotypic differences between genders and age groups. Myocarditis and myopericarditis are well described adverse events of special interest (AESI) following COVID-19 vaccinations. Although reports are reassuring regarding initial clinical outcomes, information about longer term outcomes remains limited. We aimed to further this knowledge and report outcomes to 6 months post diagnosis from a single population cohort. Reports of myocarditis following COVID-19 vaccination were followed up by SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community), the state-wide vaccine safety service for Victoria, Australia. Confirmed myocarditis cases (Brighton Collaboration Criteria levels 1–3) were followed up via surveys at 1, 3 and 6 months post symptom onset. Responses received between 22 February 2021 and 30 September 2022 were analysed. 87.5 % (N = 182) of eligible participants completed at least 1 survey report. 377 reports were analysed. 76.9 % of completed reports were from male patients. The median age of patients was 21 years [IQR: 16 to 32]. 54.8 % (n = 74) of survey reports at 6 months, reported ongoing symptoms. At all follow-up time points, females were significantly more likely to have ongoing symptoms. At 6 months, 51.9 % of male respondents reported symptom resolution compared to 22.6 % of female patients (p = 0.002). Females were also more likely to continue medication and have ongoing exercise restrictions. However, males were significantly more likely to have higher initial peak troponin results and abnormal initial cardiac imaging investigations. There appears to be a significant proportion of patients who experience ongoing symptoms to 6 months post onset amongst patients that experience these AESI. Male patients were more likely to report earlier and more complete symptom recovery, despite significantly higher average initial peak troponin. This difference in phenotypic presentation in females compared to males warrants further investigation and there is a need for longer term follow up data.